EyePoint (EYPT) Income from Continuing Operations (2010 - 2026)
EyePoint (EYPT) posted Income from Continuing Operations of 120201000.0 for Q1 2026, down 77.79% sequentially from 67609000.0 in Q4 2025, and down 129.33% YoY from 409884549.8 in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
EyePoint has reported Income from Continuing Operations for 17 years, with the latest figure at 120201000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 129.33% year-over-year to 120201000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 306968000.0 (down 99.33% YoY) and the FY2025 annual result came in at 231962000.0, down 77.25% from the prior year.
- Income from Continuing Operations fell to 120201000.0 in Q1 2026 per EYPT's latest filing, from 67609000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 16978000.0 in Q4 2023 and troughed at 120201000.0 in Q1 2026.
- A 5-year average of 53197411.76 and a median of 44295000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 643.39% in 2022, then soared 72.55% in 2023.
- Over 5 years, Income from Continuing Operations stood at 44295000.0 in 2022, then soared by 61.67% to 16978000.0 in 2023, then slumped by 143.84% to 41399000.0 in 2024, then tumbled by 63.31% to 67609000.0 in 2025, then slumped by 77.79% to 120201000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 120201000.0, 67609000.0, and 59732000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -94.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -94.47 Mn |
| Mar 31, 2026 | -87.34 Mn |
| Dec 31, 2025 | -67.71 Mn |
| Sep 30, 2025 | -59.73 Mn |
| Jun 30, 2025 | -59.43 Mn |
| Mar 31, 2025 | -48.94 Mn |
| Dec 31, 2024 | -41.50 Mn |
| Sep 30, 2024 | -29.36 Mn |
| Jun 30, 2024 | -30.83 Mn |
| Mar 31, 2024 | -33.35 Mn |
| Dec 31, 2023 | -16.33 Mn |
| Sep 30, 2023 | -14.40 Mn |
| Jun 30, 2023 | -23.20 Mn |
| Mar 31, 2023 | -22.31 Mn |
| Dec 31, 2022 | -44.38 Mn |
| Sep 30, 2022 | -19.01 Mn |
| Jun 30, 2022 | -19.95 Mn |
| Mar 31, 2022 | -19.53 Mn |
| Dec 31, 2021 | -19.44 Mn |
| Sep 30, 2021 | -16.70 Mn |